Skip to main content
  1. Home
  2. Emerging Tech
  3. Business
  4. News

UPS test drives drone delivery with mock package

Add as a preferred source on Google

With Amazon tightening its grip on the supply chain and shipping industries, older heavyweights are struggling to keep up.

But that’s not for a lack of effort. Venturing into the world of drones, UPS announced it is starting to test emergency deliveries with help from CyPhy Works, a Massachusetts-based drone company. The partnership is nothing new for UPS, as the shipping giant participated in a $22 million funding round CyPhy raised last year.

Recommended Videos

The testing began with a short 3-mile flight on Friday, about eight minutes in length, to drop a small package containing a mock asthma inhaler to a summer camp on an island in the Atlantic. While nothing here is groundbreaking, as drones from Amazon and other companies have accomplished longer journeys and carried heavier loads, the trial was meant to simply be a test drive to show UPS’ intent with drone deliveries and the technology’s potential for speedy, personalized service.

The CyPhy-UPS drone, called the Persistent Aerial Reconnaissance and Communications drone, or PARC for short, was autonomous during the flight and navigated by GPS. This specific flight model was modified, as the original was developed as a tethered drone with a wired connection to the ground to use as a power source.

Of course, a tethered drone cannot travel long distances, but it certainly has its use cases. The tethered model had recently been used to monitor traffic around a Tim McGraw concert by the Colorado Department of Transportation, according to BostInno writer Dylan Martin, who attended the UPS test flight in Massachusetts.

The PARC has a high-resolution camera with thermal imaging and target tracking abilities, and two GPS units and multiple rotors, antenna and communications systems so that if one fails, the other can be used in its place. The battery on the untethered model, used for deliveries, only lasts in the air for 40 minutes, so shorter flights would be necessary.

Harrison Kaminsky
Harrison’s obsession in the tech space originated in his father’s electronics store in Denville, New Jersey, where he…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more